BioStem Technologies Inc. (OTC:BSEM) Stock Continues To Trend Lower
Although the BioStem Technologies Inc. (OTC:BSEM) stock suffered a selloff and went down by 5% yesterday, many investors would probably be looking for a recovery this morning. Let’s take a look at the announcement that the company made yesterday.
BioStem Technologies Reports Breakthrough Results in a Diabetic Foot Ulcer Wound Closure Study Comparing BioREtain® to Standard of Care Treatment
BioStem Technologies announced on October 17 that pathbreaking results had been published in the International Wound Journal, a peer-reviewed journal. The study in question reinforced the clinical effectiveness of BioREtain processed placental membranes (RE-AC) as opposed to SOC (standard of care).
The highly specialized study proved that there were significant advantages in the healing rates over a period of 12 weeks for those treated by RE-AC as opposed to those treated with SOC.
Key Takeaways
In the news release, the company also noted that it had been regularly providing proof of the clinical efficacy of BioStem Technologies’ BioERtain technology by way of studies produced in peer-reviewed journals. However, the company also noted that as it continued to push its clinical strategy forward, it would continue to work on head-to-head studies.
These studies would be aimed at demonstrating the superior wound healing capabilities of the products from BioStem Technologies. Although the stock fell yesterday, it may be a good idea to keep an eye on the BioStem Technologies stock this morning and watch for a recovery.
CEO Quote
Jason Matuszewski, CEO of BioStem Technologies Inc., commented: “We are consistently proving the clinical effectiveness of our BioREtain technology through retrospective studies published in peer-reviewed journals. This study evaluated very challenging DFUs, characterized by long, complicated histories and significantly larger sizes compared to those seen in most controlled studies, and we are thrilled that this study highlighted the unique benefits of BioREtain-processed membranes compared to the standard of care. As we advance our clinical strategy, we will continue conducting head-to-head studies to demonstrate wound healing superiority for our products, resulting in an increase in market awareness and adoption of our products.”
Fundamentals
| P/E Ratio | 36.52 |
| PEG Ratio | 0.16 |
| Price to Book | 13.25 |
| Price to Cash Flow | 36.9405 |
| Price to Free Cash Flow | 39.4549 |
| Total Sales (TTM) | 131.44 M |
| Revenue per Share (TTM) | 6.28 |
| Shares Outstanding | 16.338 M |
| Share Float (%) | 11.82 M (72.36%) |
